BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 25154739)

  • 1. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial).
    Morgia G; Russo GI; Voce S; Palmieri F; Gentile M; Giannantoni A; Blefari F; Carini M; Minervini A; Ginepri A; Salvia G; Vespasiani G; Santelli G; Cimino S; Allegro R; Collura Z; Fragalà E; Arnone S; Pareo RM
    Prostate; 2014 Nov; 74(15):1471-80. PubMed ID: 25154739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
    Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study.
    Ryu YW; Lim SW; Kim JH; Ahn SH; Choi JD
    Urol Int; 2015; 94(2):187-93. PubMed ID: 25614155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study).
    Morgia G; Vespasiani G; Pareo RM; Voce S; Madonia M; Carini M; Ingrassia A; Terrone C; Gentile M; Carrino M; Giannantoni A; Blefari F; Arnone S; Santelli G; Russo GI;
    BJU Int; 2018 Aug; 122(2):317-325. PubMed ID: 29569389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
    Argirović A; Argirović D
    Vojnosanit Pregl; 2013 Dec; 70(12):1091-6. PubMed ID: 24450252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of
    Cai T; Cui Y; Yu S; Li Q; Zhou Z; Gao Z
    Am J Mens Health; 2020; 14(2):1557988320905407. PubMed ID: 32274957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
    Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
    BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
    Bechara A; Romano S; Casabé A; Haime S; Dedola P; Hernández C; Rey H
    J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study.
    Morgia G; Mucciardi G; Galì A; Madonia M; Marchese F; Di Benedetto A; Romano G; Bonvissuto G; Castelli T; Macchione L; Magno C
    Urol Int; 2010; 84(4):400-6. PubMed ID: 20332612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.
    Yan M; Xue P; Wang K; Gao G; Zhang W; Sun F
    Strahlenther Onkol; 2017 Sep; 193(9):714-721. PubMed ID: 28612083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
    Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
    Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serenoa Repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia.
    Minutoli L; Bitto A; Squadrito F; Marini H; Irrera N; Morgia G; Passantino A; Altavilla D
    Curr Med Chem; 2013; 20(10):1306-12. PubMed ID: 23432584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.